Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),
today announced that the Phase III IMpower132 study met its co-primary
endpoint of progression-free survival (PFS) and demonstrated that the
combination of TECENTRIQ® (atezolizumab) plus chemotherapy
(cisplatin or carboplatin plus pemetrexed) reduced the risk of disease
worsening or death (PFS) compared to chemotherapy alone in the initial
(first-line) treatment of advanced non-squamous non-small cell lung
cancer (NSCLC). While a numerical improvement for the co-primary
endpoint of overall survival (OS) was observed, statistical significance
was not met at this interim analysis, and the study will continue as
planned with final OS results expected next year. Safety for the
TECENTRIQ and chemotherapy combination appeared consistent with the
known safety profile of the individual medicines, and no new safety
signals were identified with the combination. These data will be
presented at an upcoming medical meeting.
“The IMpower132 study showed TECENTRIQ plus chemotherapy prolonged the
time people with this type of advanced lung cancer lived without their
disease worsening. We will discuss these results with health
authorities,” said Sandra Horning, M.D., chief medical officer and head
of Global Product Development.
About the IMpower132 study
IMpower132 is a Phase III, open-label, randomized study evaluating the
efficacy and safety of TECENTRIQ plus chemotherapy (cisplatin or
carboplatin and pemetrexed) versus chemotherapy alone in
chemotherapy-naïve patients with advanced non-squamous NSCLC. The study
enrolled 578 people who were randomized equally (1:1) to receive:
During the treatment-induction phase, people received TECENTRIQ,
pemetrexed and investigator’s choice of either cisplatin or carboplatin
on Day 1 of every three weeks for a dosing period of four or six cycles.
People who experienced clinical benefit during the induction phase began
maintenance therapy until disease progression.
The co-primary endpoints were:
IMpower132 met its PFS co-primary endpoint as per the study protocol.
About lung cancer
According to the American Cancer Society, it is estimated that more than
234,000 Americans will be diagnosed with lung cancer in 2018, and NSCLC
accounts for 85 percent of all lung cancers. It is estimated that
approximately 60 percent of lung cancer diagnoses in the United States
are made when the disease is in the advanced stages.
About TECENTRIQ® (atezolizumab)
TECENTRIQ is a monoclonal antibody designed to bind with a protein
called PD-L1. TECENTRIQ is designed to bind to PD-L1 expressed on tumor
cells and tumor-infiltrating immune cells, blocking its interactions
with both PD-1 and B7.1 receptors. By inhibiting PD-L1, TECENTRIQ may
enable the re-activation of T cells. TECENTRIQ may also affect normal
TECENTRIQ U.S. Indication (pronounced ‘t?-SEN-trik’)
TECENTRIQ is a prescription medicine used to treat:
A type of bladder and urinary tract cancer called urothelial
The approval of TECENTRIQ in these patients is based on a study that
measured response rate and duration of response. There is an ongoing
study to confirm clinical benefit.
A type of lung cancer called non-small cell lung cancer (NSCLC).
If your tumor has an abnormal EGFR or ALK gene, you should have also
tried an FDA-approved therapy for tumors with these abnormal genes, and
it did not work or is no longer working.
It is not known if TECENTRIQ is safe and effective in children.
Important Safety Information
What is the most important information about TECENTRIQ?
TECENTRIQ can cause the immune system to attack normal organs and
tissues and can affect the way they work. These problems can sometimes
become serious or life threatening and can lead to death.
Patients should call or see their healthcare provider right away if
they get any symptoms of the following problems or these symptoms get
TECENTRIQ can cause serious side effects, including:
Getting medical treatment right away may help keep these problems
from becoming more serious. A healthcare provider may treat patients
with corticosteroid or hormone replacement medicines. A healthcare
provider may delay or completely stop treatment with TECENTRIQ if
patients have severe side effects.
Before receiving TECENTRIQ, patients should tell their healthcare
provider about all of their medical conditions, including if they:
Patients should tell their healthcare provider about all the
medicines they take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements.
The most common side effects of TECENTRIQ in people with urothelial
The most common side effects of TECENTRIQ in people with non-small
cell lung cancer include:
TECENTRIQ may cause fertility problems in females, which may affect the
ability to have children. Patients should talk to their healthcare
provider if they have concerns about fertility.
These are not all the possible side effects of TECENTRIQ. Patients
should ask their healthcare provider or pharmacist for more information.
Patients should call their doctor for medical advice about side effects.
Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.
Report side effects to Genentech at 1-888-835-2555.
Please visit http://www.Tecentriq.com
for the TECENTRIQ full Prescribing Information for additional Important
About Genentech in Personalized Cancer Immunotherapy
For more than 30 years, Genentech has been developing medicines with the
goal to redefine treatment in oncology. Today, we’re investing more than
ever to bring personalized cancer immunotherapy (PCI) to people with
cancer. The goal of PCI is to provide each person with a treatment
tailored to harness his or her own immune system to fight cancer.
Genentech is studying more than 20 investigational medicines, 10 of
which are in clinical trials. In every study we are evaluating
biomarkers to identify which people may be appropriate candidates for
our medicines. For more information visit http://www.gene.com/cancer-immunotherapy.
About Genentech in Lung Cancer
Lung cancer is a major area of focus and investment for Genentech, and
we are committed to developing new approaches, medicines and tests that
can help people with this deadly disease. Our goal is to provide an
effective treatment option for every person diagnosed with lung cancer.
We currently have four approved medicines to treat certain kinds of lung
cancer and more than 10 medicines being developed to target the most
common genetic drivers of lung cancer or to boost the immune system to
combat the disease.
Founded more than 40 years ago, Genentech is a leading biotechnology
company that discovers, develops, manufactures and commercializes
medicines to treat patients with serious and life-threatening medical
conditions. The company, a member of the Roche Group, has headquarters
in South San Francisco, California. For additional information about the
company, please visit http://www.gene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180718005914/en/